Download PDF
Exp Clin Endocrinol Diabetes 2021; 129(07): 519-527
DOI: 10.1055/a-0961-7804
Article

Improvement in Glycemic Control in Mice of Different Age Groups

Suhadinie Gamage   *
1   Department of Nutritional Sciences, Obesity and Metabolic Health Laboratory, Texas Tech University, Lubbock, TX, USA
,
Swetha Peddibhotla
1   Department of Nutritional Sciences, Obesity and Metabolic Health Laboratory, Texas Tech University, Lubbock, TX, USA
,
P. Hemachandra Reddy
2   Internal Medicine, Cell Biology and Biochemistry, Neuroscience/Pharmacology and Neurology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
,
Nikhil V. Dhurandhar
1   Department of Nutritional Sciences, Obesity and Metabolic Health Laboratory, Texas Tech University, Lubbock, TX, USA
,
Vijay Hegde
1   Department of Nutritional Sciences, Obesity and Metabolic Health Laboratory, Texas Tech University, Lubbock, TX, USA
› Author Affiliations Funding: The study was supported by a grant from the Texas Tech University President’s collaborative grant to VH and PHR.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Aims and Methods The declining ability to control blood glucose with advancement of age is an important health risk factor and may lead to insulin resistance, type-2-diabetes and Alzheimer’s disease. Adenovirus 36(Ad36) improves glycemic control independent of insulin signaling(insulin sparing effect) as evidenced by cell, animal and observational human studies. This property of Ad36 may be useful in correcting aging-related glucose intolerance and related health conditions. Therefore, we determined the effect of Ad36 on glycemic control in older mice, to identify the age group that best responds to Ad36. Six, 12 or 20-month old C57Bl/6 mice on chow diet were each divided into weight-matched groups(mock-infected or Ad36-infected). Body weight was recorded weekly post infection (p.i.) and fasting glucose measured(week 0, 4, 8 and 20 p.i.). Blood glucose and serum insulin were measured during glucose tolerance test(week 0 and 16 p.i.). At week 20 p.i., animals were sacrificed, blood and tissues collected.

Results Mice from all age groups showed improvement in glucose clearance post Ad36 infection, but a more profound effect was observed in 6-month old mice compared with mock-infected mice. Under fed conditions though there was no difference in blood glucose at 20 wk p.i., interestingly, Ad36 reduced serum insulin in age groups old mice, compared with control mice.

Conclusions These findings suggest Ad36 infected animals improve glycemic control and clear post-prandial gluco00000se increase without increasing insulin secretion in an insulin sparing manner. These beneficial effects provide strong evidence for developing Ad36-based approaches as a novel tool to attenuate age associated glucose intolerance.

Key words

glucose intolerance - adenovirus 36 - insulin sparing - aging

* Current Address:
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI USA.




Publication History

Received: 22 April 2019
Received: 24 June 2019

Accepted: 25 June 2019

Article published online:
24 July 2019

© 2019. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 West LA, Cole S, Goodkind D. He W. 65 + in the United States: 2010 Special Studies Current Population Reports. https://wwwcommongroundhealthorg/Media/Default/documents/Senior Health/2010 Census Report_ 65-lowest_Part1pdf 2014
  • 2 Chia CW, Egan JM, Ferrucci L. Age-related changes in glucose metabolism, hyperglycemia, and cardiovascular risk. Circ Res 2018; 123: 886-904 doi:10.1161/CIRCRESAHA.118.312806
    CrossrefPubMedGoogle Scholar
  • 3 Gregg EW, Williams DE, Geiss L. Changes in diabetes-related complications in the United States. N Engl J Med 2014; 371: 286-287 doi:10.1056/NEJMc1406009
    PubMedGoogle Scholar
  • 4 Rowley WR, Bezold C, Arikan Y. et al. Diabetes 2030: Insights from yesterday, today, and future trends. Popul Health Manag 2017; 20: 6-12 doi:10.1089/pop.2015.0181
    CrossrefPubMedGoogle Scholar
  • 5 Elahi D, Muller DC. Carbohydrate metabolism in the elderly. Eur J Clin Nutr 2000; 54 (Suppl) 3 S112-S120
    CrossrefPubMedGoogle Scholar
  • 6 Helman A, Avrahami D, Klochendler A. et al. Effects of ageing and senescence on pancreatic beta-cell function. Diabetes Obes Metab 2016; 18 (Suppl) 1: 58-62 doi:10.1111/dom.12719
    CrossrefPubMedGoogle Scholar
  • 7 Pessin JE, Saltiel AR. Signaling pathways in insulin action: Molecular targets of insulin resistance. J Clin Invest 2000; 106: 165-169 doi:10.1172/JCI10582
    CrossrefPubMedGoogle Scholar
  • 8 Lin WY, Dubuisson O, Rubicz R. et al. Long-term changes in adiposity and glycemic control are associated with past adenovirus infection. Diabetes Care 2013; 36: 701-707 doi:10.2337/dc12-1089
    CrossrefPubMedGoogle Scholar
  • 9 Pasarica M, Shin AC, Yu M. et al. Human adenovirus 36 induces adiposity, increases insulin sensitivity, and alters hypothalamic monoamines in rats. Obesity (Silver Spring) 2006; 14: 1905-1913 doi:10.1038/oby.2006.222
    CrossrefPubMedGoogle Scholar
  • 10 Dhurandhar NV, Dhurandhar EJ, Ingram DK. et al. Natural infection of human adenovirus 36 in rhesus monkeys is associated with a reduction in fasting glucose 36. J Diabetes 2014; 6: 614-616 doi:10.1111/1753-0407.12178
    CrossrefPubMedGoogle Scholar
  • 11 Dhurandhar NV, Whigham LD, Abbott DH. et al. Human adenovirus Ad-36 promotes weight gain in male rhesus and marmoset monkeys. J Nutr 2002; 132: 3155-3160
    CrossrefPubMedGoogle Scholar
  • 12 Dhurandhar NV, Israel BA, Kolesar JM. et al. Transmissibility of adenovirus-induced adiposity in a chicken model. Int J Obes Relat Metab Disord 2001; 25: 990-996 doi:10.1038/sj.ijo.0801668
    CrossrefPubMedGoogle Scholar
  • 13 Dhurandhar NV, Israel BA, Kolesar JM. et al. Increased adiposity in animals due to a human virus. Int J Obes Relat Metab Disord 2000; 24: 989-996
    CrossrefPubMedGoogle Scholar
  • 14 Rogers PM, Mashtalir N, Rathod MA. et al. Metabolically favorable remodeling of human adipose tissue by human adenovirus type 36. Diabetes 2008; 57: 2321-2331 doi:db07-1311 [pii]10.2337/db07-1311
    CrossrefPubMedGoogle Scholar
  • 15 Wang ZQ, Cefalu WT, Zhang XH. et al. Human adenovirus type 36 enhances glucose uptake in diabetic and nondiabetic human skeletal muscle cells independent of insulin signaling. Diabetes 2008; 57: 1805-1813 doi:db07-1313 [pii]10.2337/db07-1313
    CrossrefPubMedGoogle Scholar
  • 16 Krishnapuram R, Dhurandhar EJ, Dubuisson O. et al. Template to improve glycemic control without reducing adiposity or dietary fat. Am J Physiol Endocrinol Metab 2011; 300: E779-E789 doi:ajpendo.00703.2010 [pii]10.1152/ajpendo.00703.2010
    CrossrefPubMedGoogle Scholar
  • 17 Andres R. Aging and diabetes. Med Clin North Am 1971; 55: 835-846
    CrossrefPubMedGoogle Scholar
  • 18 Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: A meta-analysis. Diabetes Res Clin Pract 2007; 76: 279-289 doi:10.1016/j.diabres.2006.09.010
    CrossrefPubMedGoogle Scholar
  • 19 Delea TE, Edelsberg JS, Hagiwara M. et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study. Diabetes Care 2003; 26: 2983-2989
    CrossrefPubMedGoogle Scholar
  • 20 Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129-1136 doi:10.1016/S0140-6736(07)61514-1
    CrossrefPubMedGoogle Scholar
  • 21 Lipscombe LL, Gomes T, Levesque LE. et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298: 2634-2643 doi:10.1001/jama.298.22.2634
    CrossrefPubMedGoogle Scholar
  • 22 Viljoen A, Sinclair A. Safety and efficacy of rosiglitazone in the elderly diabetic patient. Vasc Health Risk Manag 2009; 5: 389-395
    CrossrefPubMedGoogle Scholar
  • 23 Bilik D, McEwen LN, Brown MB. et al. Thiazolidinediones and fractures: Evidence from translating research into action for diabetes. J Clin Endocrinol Metab 2010; 95: 4560-4565 doi:10.1210/jc.2009-2638
    CrossrefPubMedGoogle Scholar
  • 24 Scheen AJ. New therapeutic approaches in type 2 diabetes. Acta Clin Belg 2008; 63: 402-407 doi:10.1179/acb.2008.083
    CrossrefPubMedGoogle Scholar
  • 25 Dhurandhar NV. Insulin sparing action of adenovirus 36 and its E4orf1 protein. J Diabetes Complications 2013; 27: 191-199 doi:10.1016/j.jdiacomp.2012.09.006
    CrossrefPubMedGoogle Scholar
  • 26 Goodyear LJ, Giorgino F, Sherman LA. et al. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 1995; 95: 2195-2204 doi:10.1172/JCI117909
    CrossrefPubMedGoogle Scholar
  • 27 Semple RK, Sleigh A, Murgatroyd PR. et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 2009; 119: 315-322 doi:10.1172/JCI37432
    PubMedGoogle Scholar
  • 28 Chen M, Bergman RN, Pacini G. et al. Pathogenesis of age-related glucose intolerance in man: Insulin resistance and decreased beta-cell function. J Clin Endocrinol Metab 1985; 60: 13-20 doi:10.1210/jcem-60-1-13
    CrossrefPubMedGoogle Scholar
  • 29 Stevic R, Zivkovic TB, Erceg P. et al. Oral glucose tolerance test in the assessment of glucose-tolerance in the elderly people. Age Ageing 2007; 36: 459-462 doi:10.1093/ageing/afm076
    CrossrefPubMedGoogle Scholar
  • 30 Ahmed AS, Sheng MH, Wasnik S. et al. Effect of aging on stem cells. World J Exp Med 2017; 7: 1-10 doi:10.5493/wjem.v7.i1.1
    CrossrefPubMedGoogle Scholar
  • 31 Gamage S, Reddy PH, Dhurandhar NV. et al. Potential role of E4orf1 protein in aging-associated impairment in glycemic control. J Diabetes Complications 2019; 33: 261-265 doi:10.1016/j.jdiacomp.2018.11.006
    CrossrefPubMedGoogle Scholar